| 763808 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
21 Neutrophil extracellular traps (NETs) can be measured non-invasively with CPa9-HNE – biomarker potential across different solid tumor types in the immuno-oncology setting |
2021-11-01 |
10.1136/jitc-2021-sitc2021.021 |
Jensen Christina, Thorlacius-Ussing Jeppe, Mortensen Joachim, Karsdal Morten, Willumsen Nicholas |
| 763807 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
162 Nicotinamide rejuvenates ex-vivo expanded natural killer cells and enhances their tumor killing capacity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.162 |
Pato Aviad, Hailu Astar, Brickman Nurit, Yackoubov Dima, Cichocki Frank, Peled Amnon, Simantov Ronit, Lodie Tracey, Rifman Julia, Geffen Yona, Berhani-Zipori Orit, Edri Avishay |
| 763806 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
59 Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial |
2021-11-01 |
10.1136/jitc-2021-sitc2021.059 |
Feils Arika, Erbe Amy, Birstler Jen, Kim KyungMann, Hoch Ute, Currie Sue, Nguyen Tuan, Yu Danni, Siefker-Radtke Arlene, Tannir Nizar, Hellmann Matthew, Tolaney Sara, Diab Adi, Sondel Paul |
| 763805 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
245 Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1 |
2021-11-01 |
10.1136/jitc-2021-sitc2021.245 |
Hanna Ann, Sun Xiaopeng, Gonzalez-Ericsson Paula, Sanchez Violeta, Sanders Melinda, Balko Justin |
| 763804 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
196 TLR9-activated B cells directly license adoptively transferred CD8+ T cells with potent tumor immunity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.196 |
Smith Aubrey, Knochelmann Hannah, Wyatt Megan, RIvera Guillermo Rangel, Ware Brandon, Reyes Amalia Rivera, Dwyer Connor, Neskey David, Rubinstein Mark, Liu Bei, Thaxton Jessica, Bartee Eric, Paulos Chrystal |
| 763803 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
299 Broad T antigen-specific CD8+ T cell repertoire is associated with response to PD-1 blockade in virus positive merkel cell carcinoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.299 |
Hansen Ulla, Church Candice, Bentzen Amalie, Fling Steven, Ramchurren Nirasha, Topalian Suzanne, Nghiem Paul, Hadrup Sine |
| 763802 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
204 KSQ-004: Unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.204 |
Wong Karrie, Wrocklage Christopher, Lin Sharon, Mercier Isabelle Le, Bullock Caroline, Cadzow Louise, Hohmann Anja, Shenker Sol, Sofjan Katri, Williams Leila, Kryukov Gregory, Calnan Conor, Stegmeier Frank, Benson Micah, Schlabach Michael |
| 763801 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
324 Preclinical evaluation of anti-VISTA antibody CI-8993 in a syngeneic huVISTA-KI model |
2021-11-01 |
10.1136/jitc-2021-sitc2021.324 |
Scott Fiona, Wichmann Christian, Burvenich Ingrid, McDonald Alexander, Guo Nancy, Rigopoulos Angela, Soikes Raul, Angelides Steven, Roemeling Reinhard von, Scott Andrew |
| 763800 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
423 A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.423 |
Pachynski Russell, Reimers Melissa, Weimholt Cody, Slane Katie, Oppelt Peter, Frankel Jason, Figenshau Robert, Kim Eric, Andriole Gerald, Fong Lawrence |
| 763799 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
628 Real-world clinical outcomes among patients with advanced Merkel cell carcinoma treated with avelumab in academic medical centers in the United States |
2021-11-01 |
10.1136/jitc-2021-sitc2021.628 |
Bhatia Shailender, Nghiem Paul, Phani Veeranki S, Vanegas Alejandro, Lachance Kristina, Tachiki Lisa, Chiu Kevin, Boller Emily, Bharmal Murtuza |
